-
公开(公告)号：MA45226A
公开(公告)日：2019-04-17
申请号：MA45226
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER ELISABETH , MCCALLION ORLA , SJÖGREN ANNA , ÅKERMAN MARIA
-
Patent Agency Ranking
公开(公告)号：AU2017286220A1
公开(公告)日：2018-12-06
申请号：AU2017286220
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER ELISABETH , ÅKERMAN MARIA , SJÖGREN ANNA , MCCALLION ORLA
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate- degrading bacteria
-
3.发明专利
公开(公告)号：ES2913398T3
公开(公告)日：2022-06-02
申请号：ES17730457
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER ELISABETH , ÅKERMAN MARIA , SJÖGREN ANNA , MCCALLION ORLA
Abstract: Una cápsula con revestimiento entérico para administración oral a un sujeto que la necesita, comprendiendo dicha cápsula una composición farmacéutica que comprende: (i) de un 10 % a un 25 % en peso seco de Oxalobacter formigenes, (ii) de un 50 % a un 65 % en peso seco de sacarosa; (iii) de un 10 % a un 30 % en peso seco de uno o más agentes crioconservantes y/o excipientes; en donde dicha cápsula con revestimiento entérico es para distribución de Oxalobacter formigenes al intestino delgado y/o al íleon de dicho sujeto, y en donde la actividad degradante de oxalato in vitro de Oxalobacter formigenes, cuando está presente en dicha cápsula con revestimiento entérico, no es inferior a (NLT) 100 mmol/cápsula/19 horas y en donde dicha cápsula comprende Oxalobacter formigenes en una cantidad de 109 a 1010 UFC.
-
公开(公告)号：JOP20180110A1
公开(公告)日：2019-01-30
申请号：JOP20180110
申请日：2018-12-05
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： AKERMAN MARIA , SJOGREN ANNA , LINDNER ELISABETH , MCCALLION ORLA
Abstract: يتعلقالكشفالحاليبتركيباتصيدلانيةوطرقلعلاجو/أوالوقايةمناضطراباتمتعلقةبأوكسالات. تحديداأكثر،يتعلقالكشفالحاليبتركيباتتشملبكتيريا Oxalobacter formigenes محللةللأوكسالاتالمناسبةتحديدالمعالجةو/أوالوقايةمنفرطالأوكسالاتفيالبولفيمرحلةمتأخرةيتميزبمستوياتعاليةمنالأوكسالاتفيالبلازماوانخفاضمتقدمفيوظيفةالكلى.
-
公开(公告)号：TN2018000420A1
公开(公告)日：2020-06-15
申请号：TN2018000420
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER ELISABETH , MCCALLION ORLA , SJÖGREN ANNA , ÅKERMAN MARIA
IPC: A61K35/74
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate-degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
-
公开(公告)号：CA3023042A1
公开(公告)日：2017-12-21
申请号：CA3023042
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER ELISABETH , AKERMAN MARIA , SJOGREN ANNA , MCCALLION ORLA
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate- degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
-
-
-
-
-
Search Results
6
records
(took 0.022 seconds)
